CA1050012A - Conjugat d'un medicament anticancereux avec des anticorps - Google Patents

Conjugat d'un medicament anticancereux avec des anticorps

Info

Publication number: CA1050012A
Authority: CA; Canada
Prior art keywords: drug; antibody; antibodies; daunomycin; cells
Prior art date: 1975-08-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA234,064A

Other languages

English (en)

Other versions

CA234064S (en

Inventor

Michael Sela

Ruth Arnon

Esther Hurvitz

Ruth Maron

Ron Levy

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Yeda Research and Development Co Ltd

Original Assignee

Yeda Research and Development Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-08-25

Filing date

1975-08-25

Publication date

1979-03-06

1975-08-25 Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd

1975-08-25 Priority to CA234,064A priority Critical patent/CA1050012A/fr

1979-03-06 Application granted granted Critical

1979-03-06 Publication of CA1050012A publication Critical patent/CA1050012A/fr

Status Expired legal-status Critical Current

Links

239000002246 antineoplastic agent Substances 0.000 title claims abstract description 18
229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 18
206010028980 Neoplasm Diseases 0.000 claims abstract description 32
238000000034 method Methods 0.000 claims abstract description 17
239000000203 mixture Substances 0.000 claims abstract description 16
239000000427 antigen Substances 0.000 claims abstract description 12
102000036639 antigens Human genes 0.000 claims abstract description 12
108091007433 antigens Proteins 0.000 claims abstract description 12
229940079593 drug Drugs 0.000 claims description 53
239000003814 drug Substances 0.000 claims description 53
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 20
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 20
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 20
230000000694 effects Effects 0.000 claims description 19
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 16
206010025323 Lymphomas Diseases 0.000 claims description 10
229940009456 adriamycin Drugs 0.000 claims description 8
125000000524 functional group Chemical group 0.000 claims description 7
102000004169 proteins and genes Human genes 0.000 claims description 6
108090000623 proteins and genes Proteins 0.000 claims description 6
239000000126 substance Substances 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 4
239000012279 sodium borohydride Substances 0.000 claims description 4
229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
239000002262 Schiff base Substances 0.000 claims description 3
150000004753 Schiff bases Chemical class 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
230000003647 oxidation Effects 0.000 claims description 3
238000007254 oxidation reaction Methods 0.000 claims description 3
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims description 3
WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 claims description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
201000009030 Carcinoma Diseases 0.000 claims description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
125000003277 amino group Chemical group 0.000 claims description 2
230000001093 anti-cancer Effects 0.000 claims description 2
201000008275 breast carcinoma Diseases 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 2
125000003712 glycosamine group Chemical group 0.000 claims description 2
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 2
201000008968 osteosarcoma Diseases 0.000 claims description 2
229960003171 plicamycin Drugs 0.000 claims description 2
210000001550 testis Anatomy 0.000 claims description 2
208000010570 urinary bladder carcinoma Diseases 0.000 claims description 2
208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
206010039491 Sarcoma Diseases 0.000 claims 1
208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
-1 methotestrate Chemical compound 0.000 claims 1
238000000926 separation method Methods 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 abstract description 3
238000002360 preparation method Methods 0.000 abstract description 3
210000004027 cell Anatomy 0.000 description 56
208000032839 leukemia Diseases 0.000 description 26
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 20
208000007452 Plasmacytoma Diseases 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 11
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
210000004881 tumor cell Anatomy 0.000 description 9
229940045145 uridine Drugs 0.000 description 9
241000700159 Rattus Species 0.000 description 8
108060003951 Immunoglobulin Proteins 0.000 description 7
230000003013 cytotoxicity Effects 0.000 description 7
231100000135 cytotoxicity Toxicity 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
102000018358 immunoglobulin Human genes 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000010348 incorporation Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
231100000331 toxic Toxicity 0.000 description 6
230000002588 toxic effect Effects 0.000 description 6
238000005406 washing Methods 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 5
238000003556 assay Methods 0.000 description 5
231100000433 cytotoxic Toxicity 0.000 description 5
230000001472 cytotoxic effect Effects 0.000 description 5
238000011534 incubation Methods 0.000 description 5
239000002609 medium Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
238000002054 transplantation Methods 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
230000006819 RNA synthesis Effects 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
229940127121 immunoconjugate Drugs 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
239000000047 product Substances 0.000 description 3
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001529936 Murinae Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 2
238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 2
241000700605 Viruses Species 0.000 description 2
238000010171 animal model Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
208000019420 lymphoid neoplasm Diseases 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
239000000243 solution Substances 0.000 description 2
229940043517 specific immunoglobulins Drugs 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
238000013296 A/J mouse Methods 0.000 description 1
208000004736 B-Cell Leukemia Diseases 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
102100039883 DNA-directed RNA polymerase III subunit RPC5 Human genes 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
101000669240 Homo sapiens DNA-directed RNA polymerase III subunit RPC5 Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
UYCAGRPOUWSBIQ-WOYAITHZSA-N [(1s)-1-carboxy-4-(diaminomethylideneamino)butyl]azanium;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound OC(=O)[C@@H]1CCC(=O)N1.OC(=O)[C@@H](N)CCCN=C(N)N UYCAGRPOUWSBIQ-WOYAITHZSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000005377 adsorption chromatography Methods 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000003560 cancer drug Substances 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000011694 lewis rat Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA234,064A 1975-08-25 1975-08-25 Conjugat d'un medicament anticancereux avec des anticorps Expired CA1050012A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA234,064A CA1050012A (fr)	1975-08-25	1975-08-25	Conjugat d'un medicament anticancereux avec des anticorps

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA234,064A CA1050012A (fr)	1975-08-25	1975-08-25	Conjugat d'un medicament anticancereux avec des anticorps

Publications (1)

Publication Number	Publication Date
CA1050012A true CA1050012A (fr)	1979-03-06

Family

ID=4103883

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA234,064A Expired CA1050012A (fr)	1975-08-25	1975-08-25	Conjugat d'un medicament anticancereux avec des anticorps

Country Status (1)

Country	Link
CA (1)	CA1050012A (fr)

1975
- 1975-08-25 CA CA234,064A patent/CA1050012A/fr not_active Expired

Publication	Publication Date	Title
US4263279A (en)	1981-04-21	Pharmaceutically active compositions containing adriamycin and daunomycin
Levy et al.	1975	The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies
ES2266041T3 (es)	2007-03-01	Proteina serica y celular de anclaje y conjugados.
US4093607A (en)	1978-06-06	Immunologic chemotherapeutic agents comprising antigen binding dimers covalently bound to drugs
EP0354729B1 (fr)	1994-01-12	Conjugués de médicaments cytotoxiques
US4401592A (en)	1983-08-30	Pharmaceutical composition having antitumor activity
JPS6330289B2 (fr)	1988-06-17
JPH05504554A (ja)	1993-07-15	免疫強化を促進するための方法と組成物
Flechner	1973	The cure and concomitant immunization of mice bearing Ehrlich ascites tumors by treatment with an antibody-alkylating agent complex
US5514794A (en)	1996-05-07	Antibody-drug conjugates
EP0354728A2 (fr)	1990-02-14	Conjugués de médicaments cytotoxiques
KR860001149B1 (ko)	1986-08-18	면역 글로불린 접합체의 제조방법
DK141773B (da)	1980-06-16	Fremgangsmåde til fremstilling af et antitumormiddel.
Tsukada et al.	1987	Therapeutic effect of treatment with polyclonal or monoclonal antibodies to α-fetoprotein that have been conjugated to daunomycin via a dextran bridge: studies with an α-fetoprotein-producing rat hepatoma tumor model
US5672688A (en)	1997-09-30	Immunoglobulin Fc fragment bound to an alkylating, antibiotic, or antimetabolic antitum or substance
CA1224718A (fr)	1987-07-28	Agents antitumoraux contenant des complexes du platine
CN1045621C (zh)	1999-10-13	免疫球蛋白结合物的制备方法
US5144012A (en)	1992-09-01	Cytotoxic drug conjugates
CA1050012A (fr)	1979-03-06	Conjugat d'un medicament anticancereux avec des anticorps
EP0476408A1 (fr)	1992-03-25	Conjugaison chimique de morpholino-anthracyclines avec des anticorps
EP0969872A2 (fr)	2000-01-12	Induction d'une tolerance aux cellules b
Tai et al.	1979	Tumor inhibition by chlorambucil covalently linked to antitumor globulin
Obrist et al.	1983	Enhancement of macrophage invasion of tumors by administration of chemotactic factor-antitumor antibody conjugates
Smith et al.	1974	Specificity of antileukemia sera prepared by immunization with leukemia cells admixed with normal antigen-blocking sera
Midoux et al.	1992	Activation of mouse macrophages by muramyl dipeptide coupled with an anti-macrophage monoclonal antibody